Shares of Cerecor Inc. (NASDAQ:CERC) saw an uptick in trading volume on Monday after an insider bought additional shares in the company. 5,905,802 shares were traded during mid-day trading, an increase of 1,046% from the previous session’s volume of 515,531 shares.The stock last traded at $1.66 and had previously closed at $1.18.

Specifically, major shareholder Armistice Capital Master Fund acquired 45,200 shares of Cerecor stock in a transaction on Friday, November 24th. The stock was bought at an average price of $1.20 per share, for a total transaction of $54,240.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Armistice Capital, Llc acquired 35,200 shares of Cerecor stock in a transaction on Wednesday, November 22nd. The stock was purchased at an average price of $1.20 per share, with a total value of $42,240.00. The disclosure for this purchase can be found here. Insiders acquired a total of 320,477 shares of company stock valued at $285,170 in the last quarter. Corporate insiders own 10.70% of the company’s stock.

A number of equities analysts have recently issued reports on the company. TheStreet raised Cerecor from an “e+” rating to a “c-” rating in a report on Wednesday, November 8th. ValuEngine raised Cerecor from a “strong sell” rating to a “sell” rating in a report on Tuesday, November 7th.

The company has a market capitalization of $30.74, a price-to-earnings ratio of 118.00 and a beta of 2.13.

COPYRIGHT VIOLATION NOTICE: “Cerecor (CERC) Sees Strong Trading Volume Following Insider Buying Activity” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at

Cerecor Company Profile

Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

Receive News & Ratings for Cerecor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.